JP2021509395A5 - - Google Patents

Download PDF

Info

Publication number
JP2021509395A5
JP2021509395A5 JP2020524839A JP2020524839A JP2021509395A5 JP 2021509395 A5 JP2021509395 A5 JP 2021509395A5 JP 2020524839 A JP2020524839 A JP 2020524839A JP 2020524839 A JP2020524839 A JP 2020524839A JP 2021509395 A5 JP2021509395 A5 JP 2021509395A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition according
pharmaceutically acceptable
administration
pharmaceutical
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020524839A
Other languages
English (en)
Japanese (ja)
Other versions
JP7111811B2 (ja
JP2021509395A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2018/059451 external-priority patent/WO2019090332A1/en
Publication of JP2021509395A publication Critical patent/JP2021509395A/ja
Publication of JP2021509395A5 publication Critical patent/JP2021509395A5/ja
Priority to JP2022116328A priority Critical patent/JP2022136148A/ja
Application granted granted Critical
Publication of JP7111811B2 publication Critical patent/JP7111811B2/ja
Priority to JP2024108704A priority patent/JP2024128026A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020524839A 2017-11-06 2018-11-06 がんの治療に使用するためのミルシクリブの製剤及びその治療的組み合わせ Active JP7111811B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2022116328A JP2022136148A (ja) 2017-11-06 2022-07-21 がんの治療に使用するためのミルシクリブの製剤及びその治療的組み合わせ
JP2024108704A JP2024128026A (ja) 2017-11-06 2024-07-05 がんの治療に使用するためのミルシクリブの製剤及びその治療的組み合わせ

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762582288P 2017-11-06 2017-11-06
US62/582,288 2017-11-06
PCT/US2018/059451 WO2019090332A1 (en) 2017-11-06 2018-11-06 Formulations of milciclib and therapeutic combinations of the same for use in the treatment of cancer

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022116328A Division JP2022136148A (ja) 2017-11-06 2022-07-21 がんの治療に使用するためのミルシクリブの製剤及びその治療的組み合わせ

Publications (3)

Publication Number Publication Date
JP2021509395A JP2021509395A (ja) 2021-03-25
JP2021509395A5 true JP2021509395A5 (enExample) 2021-12-16
JP7111811B2 JP7111811B2 (ja) 2022-08-02

Family

ID=64362773

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2020524839A Active JP7111811B2 (ja) 2017-11-06 2018-11-06 がんの治療に使用するためのミルシクリブの製剤及びその治療的組み合わせ
JP2022116328A Pending JP2022136148A (ja) 2017-11-06 2022-07-21 がんの治療に使用するためのミルシクリブの製剤及びその治療的組み合わせ
JP2024108704A Pending JP2024128026A (ja) 2017-11-06 2024-07-05 がんの治療に使用するためのミルシクリブの製剤及びその治療的組み合わせ

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2022116328A Pending JP2022136148A (ja) 2017-11-06 2022-07-21 がんの治療に使用するためのミルシクリブの製剤及びその治療的組み合わせ
JP2024108704A Pending JP2024128026A (ja) 2017-11-06 2024-07-05 がんの治療に使用するためのミルシクリブの製剤及びその治療的組み合わせ

Country Status (5)

Country Link
US (3) US10758541B2 (enExample)
EP (1) EP3706869A1 (enExample)
JP (3) JP7111811B2 (enExample)
CA (1) CA3076023A1 (enExample)
WO (1) WO2019090332A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7698418B2 (ja) * 2018-03-13 2025-06-25 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム Ｅｇｆｒ活性化変異を有するがんを治療するための方法
US20230019999A1 (en) * 2019-11-18 2023-01-19 Chugai Seiyaku Kabushiki Kaisha Combination drug
CN110693839B (zh) * 2019-11-19 2022-03-08 乐普药业股份有限公司 一种甲磺酸仑伐替尼固体分散体及其制备方法和用途
CN112218626B (zh) * 2019-12-31 2023-03-24 广州帝奇医药技术有限公司 一种持续释放组合物及其制备方法
JP2021167301A (ja) * 2020-04-08 2021-10-21 ファイザー・インク Ｃｄｋ２阻害剤に対する腫瘍適応を抑制するためのｃｄｋ４／６およびｃｄｋ２阻害剤による同時処置
CN112546048B (zh) * 2021-01-06 2022-11-29 天津科技大学 HKL-5-61与Osimertinib的药物组合及其应用
KR102597832B1 (ko) * 2021-01-19 2023-11-02 인천대학교 산학협력단 소라페닙의 항암효과 증진용 조성물

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
AU2007213791A1 (en) 2006-02-10 2007-08-16 Nerviano Medical Sciences S.R.L. Combinations comprising a CDK inhibitor and a growth factor antibody or anti-mitotic
EP2320903B1 (en) * 2008-07-29 2017-01-18 Nerviano Medical Sciences S.r.l. THERAPEUTIC COMBINATION COMPRISING A CDKs INHIBITOR AND AN ANTINEOPLASTIC AGENT
CN105294683B (zh) 2014-07-26 2018-01-23 广东东阳光药业有限公司 Cdk类小分子抑制剂的化合物及其用途
EP3233918A1 (en) 2014-12-19 2017-10-25 Novartis AG Combination therapies

Similar Documents

Publication Publication Date Title
JP2021509395A5 (enExample)
JP2018507243A5 (enExample)
RU2010133489A (ru) Применение ингибиторов гамма-секретазы для лечения рака
JP2010525050A5 (enExample)
JP2018514534A5 (enExample)
TWI455723B (zh) 納曲酮及安非他酮於治療超重或肥胖病患之用途
JP2019517549A5 (enExample)
JP2012521435A5 (enExample)
TW201210593A (en) Compositions and methods for treating centrally mediated nausea and vomiting
JP2015522630A5 (enExample)
JP2015038135A5 (enExample)
JP2013511507A5 (enExample)
JP2023175694A5 (enExample)
JP2025020117A5 (enExample)
JP2021152008A5 (enExample)
JP2012522837A5 (enExample)
JP2018530578A5 (enExample)
JP2016507500A5 (enExample)
JP2010538066A5 (enExample)
JP2014507475A5 (enExample)
JP2009517411A5 (enExample)
JP2024016209A5 (enExample)
JP2016505050A5 (enExample)
JP2020515523A5 (enExample)
RU2018146504A (ru) Лечение внутрипеченочных холестатических заболеваний